Phase I/IIa Study of SAR422459 in Patients With Stargardt's Macular Degeneration

Update Il y a 4 ans
Reference: NCT01367444

Woman and Man

Extract

Primary Objective: To assess the safety and tolerability of ascending doses of SAR422459 in patients with Stargardt's Macular Degeneration. Secondary Objective: To evaluate for possible biological activity of SAR422459.


Inclusion criteria

  • Stargardt Disease

Links